Oscient reiterated at strong buy by JMP

Oscient Pharmaceuticals Corp. was reiterated at strong buy with a target price of $6.00 by JMP Securities analyst Adam Cutler. JMP noted for the week ended Sept. 2 there were 2,618 prescriptions for Oscient's Factive, a drug for pneumonia, bronchitis and sinusitis, and it views the company as undervalued. Oscient shares closed down $0.08, or 3.23%, at $2.40 on Monday on volume of 849,063 shares versus a three-month trailing average of 819,729 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.